[
  {
    "ts": null,
    "headline": "FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients",
    "summary": "Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients.",
    "url": "https://finnhub.io/api/news?id=67301685639e1cbed569071dbcaaec77e88d4bf5205825395785c457dd6e8348",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746116166,
      "headline": "FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients",
      "id": 134173926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients.",
      "url": "https://finnhub.io/api/news?id=67301685639e1cbed569071dbcaaec77e88d4bf5205825395785c457dd6e8348"
    }
  },
  {
    "ts": null,
    "headline": "Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis",
    "summary": "IRVINE, Calif., May 01, 2025--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.",
    "url": "https://finnhub.io/api/news?id=1533d318a84c58779639a6514fc21fb9233b13029fe7b78db65477a6f7ed9d4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746100800,
      "headline": "Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis",
      "id": 134173927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "IRVINE, Calif., May 01, 2025--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.",
      "url": "https://finnhub.io/api/news?id=1533d318a84c58779639a6514fc21fb9233b13029fe7b78db65477a6f7ed9d4f"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite?",
    "summary": "We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other stocks that Jim Cramer recently discussed. During the most recent episode of Mad Money, Jim Cramer revisited the recent turbulence in […]",
    "url": "https://finnhub.io/api/news?id=47a262b5b264883dd5f120c2ccfeb758d1ea185b1612ceeec873b03e1fce5c0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746057791,
      "headline": "Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite?",
      "id": 134166066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other stocks that Jim Cramer recently discussed. During the most recent episode of Mad Money, Jim Cramer revisited the recent turbulence in […]",
      "url": "https://finnhub.io/api/news?id=47a262b5b264883dd5f120c2ccfeb758d1ea185b1612ceeec873b03e1fce5c0d"
    }
  }
]